Evaluation of the pre-clinical efficacy of baicalin in reversing hypoxia-induced sorafenib resistance in hepatocellular carcinoma
Grant Data
Project Title
Evaluation of the pre-clinical efficacy of baicalin in reversing hypoxia-induced sorafenib resistance in hepatocellular carcinoma
Principal Investigator
Dr Tan, Hor Yue Hoey
(Principal Investigator (PI))
Co-Investigator(s)
Dr Wang Ning
(Co-Investigator)
Professor Feng Yibin
(Co-Investigator)
Duration
18
Start Date
2019-04-01
Amount
94800
Conference Title
Evaluation of the pre-clinical efficacy of baicalin in reversing hypoxia-induced sorafenib resistance in hepatocellular carcinoma
Presentation Title
Keywords
baicalin, carcinoma, hepatocellular, hypoxia-induced, pre-clinical, sorafenib
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
16171511
Grant Type
Health and Medical Research Fund - Mini Grant
Funding Year
2018
Status
Completed
Objectives
Hepatocellular carcinoma (HCC) is a high mortality-associated malignancy, owing to the lack of effective treatment for unresectable advanced patients. Sorafenib is the first approved oral therapy that offered survival benefit for advanced patients, nonetheless most patients progressed after short term of sorafenib treatment. Tumor hypoxia, an oxygen deprived condition that result from persistent sorafenib intervention, partially contributed to HCC resistance to sorafenib. HIF-1α, which accumulates in sorafenib-resistant HCC cells, is the transcription factor mediating hypoxia process and its target genes highly regulates HCC aggressiveness. Thus, using agents target on HIF-1α would overcome hypoxia-induced sorafenib resistance in HCC.